Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1439A in treatment-naive HIV-1 patients with selected transmitted NNRTI resistance mutations
2015-003616-20Phase 2Unknown
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doravirine, lamivudine and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Primary endpoints: HIV-1 RNA suppression at Week 48 and Safety and tolerability. Status: unknown.
02
Drugs
doravirinelamivudinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-003616-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003616-20.